NASDAQ:ABMD

Abiomed Stock Forecast, Price & News

$296.57
-4.22 (-1.40 %)
(As of 05/6/2021 10:37 AM ET)
Add
Compare
Today's Range
$296.50
$300.65
50-Day Range
$294.14
$351.17
52-Week Range
$180.29
$387.40
Volume1,541 shs
Average Volume312,770 shs
Market Capitalization$13.41 billion
P/E Ratio65.18
Dividend YieldN/A
Beta1.41
30 days | 90 days | 365 days | Advanced Chart
Receive ABMD News and Ratings via Email

Sign-up to receive the latest news and ratings for Abiomed and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ABMD
CUSIP00365410
Phone978-646-1400
Employees1,536
Year Founded1981

Sales & Book Value

Annual Sales$840.88 million
Cash Flow$4.74 per share
Book Value$23.64 per share

Profitability

Net Income$203.01 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap$13.41 billion
Next Earnings Date8/5/2021 (Estimated)
OptionableOptionable

Social Links


Headlines

See More Headlines
Abiomed logo

About Abiomed

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; and Impella Connect, a cloud-based technology that enables secure, cloud-based, and remote viewing of the Automated Impella Controller for physicians and hospital staffs. In addition, the company engages in the development of Impella XR Sheath, a sheath designed to expand and recoil to all for ease of use upon insertion of an Impella heart pump and minimize the size of the arteriotomy; Impella BTR, a percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

MarketRank

Overall MarketRank

1.65 out of 5 stars

Medical Sector

341st out of 2,043 stocks

Surgical & Medical Instruments Industry

30th out of 169 stocks

Analyst Opinion: 2.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Abiomed (NASDAQ:ABMD) Frequently Asked Questions

Is Abiomed a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Abiomed in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Abiomed stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABMD, but not buy additional shares or sell existing shares.
View analyst ratings for Abiomed
or view top-rated stocks.

What stocks does MarketBeat like better than Abiomed?

Wall Street analysts have given Abiomed a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Abiomed wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Abiomed's next earnings date?

Abiomed is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Abiomed
.

How were Abiomed's earnings last quarter?

Abiomed, Inc. (NASDAQ:ABMD) released its quarterly earnings data on Wednesday, April, 28th. The medical equipment provider reported $1.24 earnings per share for the quarter, beating analysts' consensus estimates of $1.10 by $0.14. The medical equipment provider had revenue of $241.30 million for the quarter, compared to analyst estimates of $231.13 million. Abiomed had a trailing twelve-month return on equity of 15.34% and a net margin of 25.89%. The company's revenue for the quarter was up 16.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.70 earnings per share.
View Abiomed's earnings history
.

How has Abiomed's stock price been impacted by COVID-19 (Coronavirus)?

Abiomed's stock was trading at $151.13 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ABMD stock has increased by 98.2% and is now trading at $299.54.
View which stocks have been most impacted by COVID-19
.

What guidance has Abiomed issued on next quarter's earnings?

Abiomed issued an update on its FY 2022 earnings guidance on Thursday, May, 6th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $990 M-$1.03 billion, compared to the consensus revenue estimate of $998.13 million.

What price target have analysts set for ABMD?

5 brokerages have issued twelve-month price objectives for Abiomed's shares. Their forecasts range from $245.00 to $425.00. On average, they expect Abiomed's stock price to reach $348.33 in the next twelve months. This suggests a possible upside of 16.3% from the stock's current price.
View analysts' price targets for Abiomed
or view top-rated stocks among Wall Street analysts.

Who are Abiomed's key executives?

Abiomed's management team includes the following people:
  • Mr. Michael R. Minogue, Chairman, CEO & Pres (Age 54, Pay $1.68M) (LinkedIn Profile)
  • Mr. Todd A. Trapp, CFO & VP (Age 50, Pay $800.98k) (LinkedIn Profile)
  • Dr. David M. Weber, Sr. VP & COO (Age 60, Pay $752.48k) (LinkedIn Profile)
  • Mr. Michael G. Howley, VP & GM of Global Sales (Age 57, Pay $522.56k) (LinkedIn Profile)
  • Mr. Andrew J. Greenfield, VP & Chief Commercial Officer (Age 48, Pay $547.39k) (LinkedIn Profile)
  • Dr. Thorsten Siess Ph.D., VP & CTO
  • Ms. Ingrid Goldberg Ward, Director of Investor Relations
  • Mr. Marc A. Began, VP, Gen. Counsel & Sec. (Age 54) (LinkedIn Profile)
  • Sarah Karr, Communications Mang.
  • Ms. Karen Mahoney, Head of Global HR

What is Michael R. Minogue's approval rating as Abiomed's CEO?

96 employees have rated Abiomed CEO Michael R. Minogue on Glassdoor.com. Michael R. Minogue has an approval rating of 72% among Abiomed's employees.

Who are some of Abiomed's key competitors?

What other stocks do shareholders of Abiomed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abiomed investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Align Technology (ALGN), Arista Networks (ANET), Intuitive Surgical (ISRG), Square (SQ), Netflix (NFLX), Adobe (ADBE) and salesforce.com (CRM).

What is Abiomed's stock symbol?

Abiomed trades on the NASDAQ under the ticker symbol "ABMD."

Who are Abiomed's major shareholders?

Abiomed's stock is owned by a number of retail and institutional investors. Top institutional investors include Villere ST Denis J & Co. LLC (0.55%), Chicago Capital LLC (0.33%), Sumitomo Mitsui Trust Holdings Inc. (0.32%), Scout Investments Inc. (0.24%), Geneva Capital Management LLC (0.23%) and Marathon Asset Management LLP (0.22%). Company insiders that own Abiomed stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Martin P Sutter, Michael R Minogue and Paul Thomas.
View institutional ownership trends for Abiomed
.

Which institutional investors are selling Abiomed stock?

ABMD stock was sold by a variety of institutional investors in the last quarter, including Los Angeles Capital Management LLC, Country Trust Bank, Nisa Investment Advisors LLC, Zurcher Kantonalbank Zurich Cantonalbank , Sumitomo Mitsui Trust Holdings Inc., NN Investment Partners Holdings N.V., Geneva Capital Management LLC, and Retirement Systems of Alabama. Company insiders that have sold Abiomed company stock in the last year include Andrew J Greenfield, Dorothy E Puhy, Martin P Sutter, Michael R Minogue, and Paul Thomas.
View insider buying and selling activity for Abiomed
or view top insider-selling stocks.

Which institutional investors are buying Abiomed stock?

ABMD stock was acquired by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Verde Servicos Internacionais S.A., Scout Investments Inc., Commerce Bank, Assenagon Asset Management S.A., DnB Asset Management AS, PGGM Investments, and Envestnet Asset Management Inc..
View insider buying and selling activity for Abiomed
or or view top insider-buying stocks.

How do I buy shares of Abiomed?

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Abiomed's stock price today?

One share of ABMD stock can currently be purchased for approximately $299.54.

How much money does Abiomed make?

Abiomed has a market capitalization of $13.55 billion and generates $840.88 million in revenue each year. The medical equipment provider earns $203.01 million in net income (profit) each year or $4.74 on an earnings per share basis.

How many employees does Abiomed have?

Abiomed employs 1,536 workers across the globe.

Does Abiomed have any subsidiaries?

The following companies are subsidiares of Abiomed: ABD Holding Company, ABIOMED Athlone Ltd, ABIOMED Australia Pte. Ltd, ABIOMED Europe, ABIOMED Japan KK, ABIOMED Limited, ABIOMED R&D, ABIOMED SARL, ABIOMED Singapore Pte. Ltd, AIS GmbH Aachen Innovative Solutions, ECP Entwicklungsgesellschaft mbH, and Impella Cardiosystems.

When was Abiomed founded?

Abiomed was founded in 1981.

What is Abiomed's official website?

The official website for Abiomed is www.abiomed.com.

Where are Abiomed's headquarters?

Abiomed is headquartered at 22 CHERRY HILL DR, DANVERS MA, 01923.

How can I contact Abiomed?

Abiomed's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]


This page was last updated on 5/6/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.